Novartis drug shows efficacy in late-stage trial for chronic urticaria.

Novartis presented positive data from its RemIND trial, indicating that Rhapsido (remibrutinib) met primary endpoints across common chronic inducible urticaria (CIndU) subtypes. This makes Rhapsido the first treatment to demonstrate efficacy in a global Phase III clinical trial for CIndU. The drug is currently undergoing review by the FDA, potentially offering a new targeted therapy for this condition.